Your session is about to expire
← Back to Search
Suprachoroidal Microcatheterization with Triamcinolone for Diabetic Macular Edema (CAPE Trial)
CAPE Trial Summary
This trial tests a new device to treat Diabetic Macular Edema with a drug to see how safe & tolerable it is.
CAPE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAPE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAPE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have swelling in the central part of my retina due to diabetes.I have had specific laser treatments in my eye within the last 16 weeks.I have diabetes (Type 1 or Type 2).I have had cancer or still have it within the last five years.I have not used long-term steroid eye implants.My study eye's vision won't get better from treating swelling.My eye condition is due to advanced diabetes.I had an eye injection for VEGF within the last 4 weeks.I have never had treatment with steroids injected into my eye.My diabetes or another systemic disease is not under control.My eye treatment injections didn’t work well or at all.My macular edema is not caused by diabetes.I haven't had steroid eye treatments with triamcinolone or Ozurdex® recently.
- Group 1: Suprachoroidal Triamcinolone acetonide 4.0mg
- Group 2: Suprachoroidal Triamcinolone acetonide 2.4mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently open to this trial?
"Yes, this clinical trial is still accepting applicants. The first listing on the trials website was posted on August 31st 2022 and the latest edit occurred January 17th 2023."
What is the upper limit of participants in this clinical trial?
"The trial necessitates 20 individuals that meet the prerequisites to be enrolled. These participants can register at two locations in Minnesota and Texas, respectively; Minneapolis, MN's Minnesota I - Oxular Investigational Site or Austin, TX's Austin I - Oxular Investigational Site."
How many medical establishments are conducting this clinical investigation?
"At present, 6 clinical trial sites are looking for participants. These locations include Minneapolis, Austin and Houston but also other cities in the US. It is recommended that potential patients select a participating site closest to them to reduce transportation requirements if they choose to register."
Has Suprachoroidal Triamcinolone acetonide 2.4mg been granted authorization by the FDA?
"This Phase 2 trial has generated sufficient evidence to indicate the safety of Suprachoroidal Triamcinolone acetonide 2.4mg, so it was awarded a score of two on our scale from 1-3."
Share this study with friends
Copy Link
Messenger